Clinical trial · Interventional
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
NCT00969917CI-TRIAL-00017501withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Company decision not to start the study
Summary
Brief summary (as posted)
The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dedifferentiated Liposarcoma | Dedifferentiated Liposarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IPI-504 | Drug | Retaspimycin Hydrochloride | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- IPI-504
- description
- IPI 504 administered twice weekly for 2 weeks followed by 1 week off treatment
- interventionNames
- Drug: IPI-504
Primary outcomes (1)
- measure
- To determine the safety profile and overall response rate (ORR) of IPI 504 in patients with advanced dedifferentiated liposarcoma.
- timeFrame
- Every 6 weeks
Secondary outcomes (1)
- measure
- To determine the clinical benefit rate and duration of overall response
- timeFrame
- Every 6 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * At least 18 years of age at the time of signing informed consent. * Histologic diagnosis of dedifferentiated liposarcoma. * Available archival pathology specimen or tissue sample from a new biopsy for confirmation of diagnosis by central pathology reading. * At least one prior chemotherapy regimen for dedifferentiated liposarcoma. * No more than 2 prior chemotherapy regimens for dedifferentiated liposarcoma. Note: Any number of non-chemotherapy regimens is permitted. * Measurable disease on computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST (version 1.1) with at least one measurable lesion. * Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1. * Life expectancy ≥6 months. Exclusion Criteria: * Prior treatment with any heat shock protein 90 (Hsp90) inhibitor. * Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease * Patients with prior hepatic resections or hepatic-directed therapy * Use of a medication or food that is a clinically relevant CYP3A inhibitor or inducer within 2 weeks prior to dosing.
References
Publications (0)
Data not yet available
No reference posted for this study.